Biofrontera Overview

  • Founded
  • 1997
  • Status
  • Public
  • Employees
  • 154
  • Stock Symbol
  • B8F
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $3.32
  • (As of Monday Closing)

Biofrontera General Information


Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Personal Products
Stock Exchange
Primary Office
  • Hemmelrather Weg 201
  • 51377 Leverkusen
  • Germany
+49 0214 000000

Biofrontera Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biofrontera Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.32 $3.47 $2.65 - $6.52 $188M 56.7M 53.6K -$0.21

Biofrontera Financials Summary

In Thousands,
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 172,782 195,984 229,242 245,477
Revenue 34,196 34,592 34,999 24,908
EBITDA (8,886) (5,352) 1,078 (19,772)
Net Income (14,449) (14,845) (8,237) (10,477)
Total Assets 90,356 69,359 65,377 44,764
Total Debt 28,110 29,365 26,125 15,588
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biofrontera Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biofrontera‘s full profile, request access.

Request a free trial

Biofrontera Executive Team (5)

Name Title Board Seat Contact Info
Hermann Lubbert Ph.D Chief Executive Officer & Executive
Thomas Schaffer Chief Financial Officer, Finance & Executive
Erica Monaco Chief Financial Officer
Christopher Pearson Chief Commercial Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Biofrontera Board Members (2)

Name Representing Role Since
Franca Ruhwedel Biofrontera Board Member 000 0000
Kevin Weber Biofrontera Board Member 000 0000
To view Biofrontera’s complete board members history, request access »

Biofrontera Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biofrontera Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biofrontera‘s full profile, request access.

Request a free trial

Biofrontera Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000 00000 25-Mar-2019 000000000000000000 Drug Discovery
Allergan (Ameluz & BF-RhodoLED Distribution) 07-Nov-2014 Merger/Acquisition Drug Delivery
To view Biofrontera’s complete acquisitions history, request access »